Two Rezulin Panelists Have Ties to Drug's Maker, LA Times Says
Bloomberg News
March 25, 1999, 9:39 a.m. ET
Washington, March 25 (Bloomberg) -- Two new members of an
expert panel set to review the safety of Warner Lambert Co.'s
diabetes drug Rezulin tomorrow have received money from a
diabetes education group funded by Warner Lambert and its
Japanese partner, the Los Angeles Times said. The two new
members, Mayer Davidson and Saul Genuth, were named to
Endocrinologic and Metabolic Drugs Advisory Committee, which will
review the safety of Rezulin following reports of deaths from
liver damage, the newspaper said. Davidson told the Times he
divulged his connections to Warner Lambert to the FDA, and he
said he would leave it to the agency to determine whether there
was a conflict of interest.
Panel members are required to disclose any links they may
have to companies they review, and FDA regulations determine
whether they are allowed to vote at the meeting.
(LAT 3/25 A1 www.latimes.com)
|
